Supply of the product Brentuximab Vedotin (rch) (Adcetris) by Nycomed Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to provide a legislative framework for the regulation of therapeutic goods in Australia. The Act was introduced to address the need for a cohesive and comprehensive system to manage the supply, quality, efficacy, and safety of therapeutic goods, including medicines, medical devices, and blood products. Enacted by the Parliament of Australia, the primary policy objective of the Act is to protect public health by ensuring that only therapeutic goods that meet safety, quality, and efficacy standards are available in the market. One of the mechanisms through which this is achieved is the issuance of consents under sections 14 and 14A, which allow for the supply of therapeutic goods that do not fully comply with specific regulatory standards, provided certain conditions are met to mitigate any potential risks to public health. This approach allows for flexibility in the regulation while maintaining the overarching goal of safeguarding public health.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, including medicines, medical devices, and blood products, among others. The Act applies to all entities and individuals involved in the supply and regulation of these goods, encompassing a broad range of industries and conduct. Specifically, the Act extends its jurisdiction across the Commonwealth of Australia, establishing a national framework for the control and oversight of therapeutic goods. The Act includes provisions for exemptions and thresholds, often delineated through subordinate instruments such as regulations and orders. For instance, in the case of brentuximab vedotin (rch) (ADCETRIS), the Therapeutic Goods Administration granted a specific consent for its supply under certain conditions, such as the inclusion of the approved Australian Product Information and adherence to a set expiry date. This demonstrates the Act’s ability to tailor its application to specific therapeutic goods through targeted regulatory measures.

Key Provisions

The main operative sections of the Therapeutic Goods Act 1989, specifically sections 14 and 14A, pertain to the supply of therapeutic goods that do not fully comply with all the requirements of Therapeutic Goods Orders. Section 14 allows the delegate of the Secretary of the Department of Health to consent to the supply of such non-compliant products under certain conditions, while Section 14A details the specific conditions that must be adhered to. In this case, the Secretary’s delegate has consented to the supply of brentuximab vedotin (rch) (ADCETRIS) 50 mg powder for injection vial, manufactured by Nycomed Pty Ltd, which does not conform with all the requirements of Therapeutic Goods Order (TGO) 69. The obligations imposed on the parties involved by this Act are significant. Firstly, Nycomed Pty Ltd must ensure that the approved Australian Product Information accompanies each carton supplied of the non-compliant therapeutic product. This information is crucial for healthcare professionals and patients to understand the safe use and potential risks associated with the product. Additionally, the consent provided by the Secretary's delegate is time-bound and expires on December 19, 2014, thereby limiting the duration for which the non-compliant product can be supplied. Any changes to the product beyond those specified must also be avoided unless otherwise permitted. Failure to comply with the conditions set forth in the Act and the Secretary's consent can lead to serious consequences. Under Section 15(1), the consent may be revoked, and the non-compliant product may no longer be supplied. Furthermore, breaches of the Therapeutic Goods Act 1989 can result in both civil and criminal penalties. For example, supplying non-compliant therapeutic goods can result in fines up to $330,000 for an individual or $1.65 million for a corporation, as stipulated in Section 33C of the Act. Additionally, imprisonment terms may apply, depending on the severity and intent of the breach. These penalties underscore the importance of adhering to the regulatory requirements set by the Therapeutic Goods Administration.